Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group

H Bell, K Hellum, S Harthug, B Myrvang, S Ritland, A Maeland, B von der Lippe, K Bjøro, K Skaug, B G Gutigard, N Raknerud, P Simmonds

Research output: Contribution to journalArticlepeer-review

Abstract

Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been promising, with up to 50% sustained hepatitis C virus (HCV) RNA response. The aim of this study was to investigate whether a sustained HCV RNA response could be obtained with combination therapy in patients who were non-responders or relapsers after IFN treatment.
Original languageEnglish
Pages (from-to)194-8
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 1999

Keywords

  • Adult
  • Antiviral Agents
  • Biopsy
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Hepacivirus
  • Hepatitis C, Chronic
  • Humans
  • Interferon-alpha
  • Male
  • Middle Aged
  • RNA, Viral
  • Recombinant Proteins
  • Ribavirin
  • Viremia

Fingerprint Dive into the research topics of 'Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group'. Together they form a unique fingerprint.

Cite this